You just read:

German Federal Joint Committee (G-BA) Confirms Evidence for Additional Benefit for CINQAERO® (reslizumab) in Severe Asthma Patients with an Elevated Eosinophil Count

News provided by

Teva Pharmaceuticals Europe BV

06 Jul, 2017, 17:15 BST